

UNITED STATES OF AMERICA

DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I arr/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled: ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS and the specification of which is attached hereto (Aventis Docket No.DEAV2002/0058 US NP) was filed on August 7, 2003 as U.S. Application Number 10/636,001 and was amended on (if applicable). was described and claimed in PCT Int'l Application Number filed (check one) filed on and as amended under PCT Article 19 on (if any). IWe hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.

I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56. X I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: 07/08/2002 Day/Month/Year Filed 02017587.3 Number Foreign European Country Priority: Prior Number Foreign Country Day/Month/Year Filed Appin(s): 図 I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below: December 10, 2002 Filing Date 60/432,312 Number I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. Application Serial No. Filing Date Status (Patented, Pending) I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. inventors(s): Additional names and signatures are attached.

1. Full name: Hartmut STROBEL
Signature: fail ha
Date: 1 11 11 3 3
Country of Citizenship: GERMANY
Residence: Liederbach, Germany
(City and State/City and Country only)
P. O. Address: Erlenweg 22
65835 Liederbach, Germany
3. Full name: Peter BELOW
P 1 01
Signature: Pere for n
Date: 2003-11-12
Country of Citizenship: GERMANY
Residence: Frankfurt, Germany
(City and State/City and Country only)
P. O. Address: Volklinger Weg 62
60529 Frankfurt, Germany

2. Full name: Paulus WOHLFART

Signature: Cuilu Uccul

Date: Local Local

Country of Citizenship: GERMANY

Residence: Bensheim, Germanv
(City and State/City and Country only)

P. O. Address: Bertolt-Brecht-Ring 16c
64625 Bensheim, Germany

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0058 US NP

Aventis Docket No. DEAV2002/0058 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: STROBEL, tal.

Examiner:

Serial No.:

10/636,001

Group Art Unit.:

1626

Filed:

August 7, 2003

Title:

ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

We, Markus Jacobi and Hans-Jürgen Fischer, Authorized Sign	
Aventis Pharma Deutschland GmbH, Assignee of the above-identified Application, hereb	y appoint
the attorneys and/or agents associated with the Customer No.(s) provided below as attorned	
agents with full power to prosecute this application on behalf of Assignee and to trans	act all of
Assignee's business in connection with the above-identified Application in the Patent and I	rademark
Office:	

Customer No.: 005487

Effective Date:

August 7, 2003

By:

Markus Jacobi

By:

Hans-Jürgen Fischer

Title:

Prokurist

Title:

<u>Handlungsbevollmächtigter</u>

Date:

November 18, 2003

Date:

November 18, 2003

Address correspondence and telephone calls to: Julie Anne Knight, Reg. No. 48,867 Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626